相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Review
Medicine, General & Internal
Daniel Apolinar Garcia Estevez et al.
Summary: Myasthenia gravis is an autoimmune disease characterized by fatigueable muscle weakness caused by specific antibodies attacking the neuromuscular junction. The thymus plays a central role in its development, and the most common pathogenic antibodies target acetylcholine receptor. Advances in understanding the immunological components of the neuromuscular junction have led to the identification of new pathogenic antibodies, reduced the percentage of seronegative myasthenia patients, and proposed a classification for different subgroups of patients. Furthermore, new drugs have been developed for the treatment of myasthenia gravis patients refractory to conventional immunosuppressive treatment.
Article
Clinical Neurology
Kristi Jackson et al.
Summary: This study conducted one-on-one interviews with 28 gMG patients in the US to understand their experiences with symptoms, the most bothersome symptoms, and the impact on their daily lives, as well as their treatment goals. The results showed that the fluctuating and unpredictable nature of gMG symptoms have a substantial impact on patients' emotional, social, and economic well-being. Participants' treatment goals highlighted the importance of achieving symptom stability to resume a normal lifestyle quickly.
NEUROLOGY AND THERAPY
(2023)
Review
Immunology
Sruthi S. Nair et al.
Summary: Myasthenia gravis, an autoimmune neurological disease, has traditionally been treated with corticosteroids, immunotherapy, and cholinesterase inhibitors. However, treatment-resistant MG and long-term toxicities have posed challenges. Recent advancements in immunology have led to the development of newer, more targeted therapies such as complement inhibitors, neonatal Fc receptor blockers, and B cell-depleting agents like rituximab. This review examines the evidence for these novel therapies and their clinical considerations.
IMMUNOTARGETS AND THERAPY
(2023)
Article
Medicine, Research & Experimental
S. Dewilde et al.
Summary: This study aimed to estimate the impact of myasthenia gravis (MG) on the health-related quality of life, medical burden, and need for caregiver help. The results showed that MG has a significant negative impact on patients, affecting their vision, swallowing, speech, mobility, dexterity, and breathing, and requiring more caregiver assistance and medical resources.
ADVANCES IN THERAPY
(2023)
Article
Ophthalmology
Parinee Kemchoknatee et al.
Summary: This study described and compared the baseline characteristics and outcomes of OMG patients in Thailand classified by onset groups, and investigated the factors associated with the disease, particularly in terms of treatment responses based on MGFA-PIS. The results showed that a lower dose of pyridostigmine was more commonly used in the early-onset group, while the mean dose of corticosteroids was significantly lower in the late-onset patients. Seropositivity of acetylcholine receptor antibody decreased the likelihood of achieving minimal manifestations, while a higher dose of pyridostigmine increased the likelihood of achieving it.
INTERNATIONAL OPHTHALMOLOGY
(2023)
Article
Clinical Neurology
Sophie Lehnerer et al.
Summary: Patients with myasthenia gravis (MG) have lower health-related quality of life (HRQoL) compared to the general population, with economic, social, and emotional aspects contributing to the burden of the disease. Factors associated with lower HRQoL in MG patients include female gender, older age, low income, lack of partner, limited daily activities, symptoms of depression, anxiety, fatigue, and perceived low social support.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Aysegul Akkan Suzan et al.
Summary: This study aimed to evaluate the frequency of fatigue in myasthenic patients with nearly full muscle strength and the effect of fatigue on quality of life. Results showed that fatigue was associated with depression and daytime sleepiness.
ACTA NEUROLOGICA BELGICA
(2022)
Article
Immunology
Christopher Nelke et al.
Summary: Myasthenic crisis and disease exacerbation impose a high burden on patients with myasthenia gravis. Disease severity at diagnosis and antibody status can predict the occurrence of crisis and exacerbation. Intensified monitoring and prevention of infectious complications may help prevent uncontrolled disease in MG patients.
JOURNAL OF NEUROINFLAMMATION
(2022)
Article
Public, Environmental & Occupational Health
Valentina Ignatova et al.
Summary: This study estimated the annual costs of MG patients in Bulgaria from a societal perspective and found that direct healthcare costs slightly outweighed indirect costs, with drug costs having the biggest impact. Severe generalized disease, disease crises, and recurrent infections were identified as significant cost drivers. The reliance on family members as informal caregivers among Bulgarian MG patients was common, likely due to the lack of access to appropriate social services. Further research and targeted health policies are needed to meet the needs of these patients.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Multidisciplinary Sciences
Derin Marbin et al.
Summary: This study aimed to assess the impact of depression symptoms and self-perceived MG severity on the quality of life and caregiver burden of MG patients. The results showed that besides the severity of MG, depression symptoms also have negative effects on both the quality of life of patients and the burden of caregivers.
SCIENTIFIC REPORTS
(2022)
Article
Clinical Neurology
Robert Pascuzzi et al.
Summary: Myasthenia Gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most common disorders involving defective neuromuscular transmission in clinical practice. Patients often experience fatigable weakness and fluctuation in symptoms, regardless of whether the etiology is autoimmune, paraneoplastic, genetic, or toxic. Autoimmune MG is the most prevalent neuromuscular transmission disorder in adults, while LEMS is comparatively rare but requires familiarity with its clinical presentation, diagnosis, and management.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2022)
Article
Clinical Neurology
Linda Harris et al.
Review
Clinical Neurology
Mingxia Li et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2019)
Article
Psychology, Clinical
Jafet Arrieta et al.
JOURNAL OF CLINICAL PSYCHOLOGY
(2017)
Article
Medicine, General & Internal
Seohyun Kim et al.
Review
Medicine, General & Internal
Nils E. Gilhus
NEW ENGLAND JOURNAL OF MEDICINE
(2016)
Review
Clinical Neurology
Nils Erik Gilhus et al.
Article
Health Care Sciences & Services
Shan Wang et al.
BMC HEALTH SERVICES RESEARCH
(2014)
Review
Medicine, General & Internal
Winnie Chi-Man Yip et al.
Article
Medicine, General & Internal
A Vincent et al.
